NEW YORK, Sept. 23, 2021 /PRNewswire/ — Oppenheimer & Co. Inc. (“Oppenheimer”) – a number one funding financial institution, wealth supervisor, and a subsidiary of Oppenheimer Holdings (NYSE: OPY) – at present introduced that it has efficiently concluded its Fall Healthcare Life Sciences & MedTech Summit. The occasion, held just about from September 20 – 23, introduced collectively over 151 main private and non-private corporations from throughout the life sciences and medical expertise sectors to debate key developments and alternatives with buyers.
Michael Margolis, R.Ph., Oppenheimer’s Co-Head of Healthcare Funding Banking and Head of Healthcare Life Sciences Funding Banking, mentioned, “The previous 12 months has been an lively time for all times sciences and med tech corporations searching for to lift capital, develop new and revolutionary options and speed up their time-to-market. We had been more than happy to supply corporations and buyers the chance to attach at our Healthcare Life Sciences & MedTech Summit and to assist the business transfer ahead.”
Thursday, September 23 was the Summit’s Non-public Firm Day, specializing in a choose group of personal corporations within the rising biotechnology and life science sectors. Moreover, Oppenheimer’s healthcare life science and med tech fairness analysis analysts facilitated discussions and questions for the businesses. Analysts in attendance included:
- Matt Biegler, MA – Biotechnology
- Mark Breidenbach, Ph.D. – Biotechnology
- Francois Brisebois, M.Sc. – Biotechnology
- Kevin DeGeeter – Biotechnology and Diagnostics
- Leland Gershell, MD, Ph.D. – Biopharmaceuticals
- Jeff Jones, Ph.D. – Biotechnology
- Suraj Kalia, MBA, CFA – Medical Expertise and Gadgets
- Justin Kim, MBA, MSF – Biotechnology
- Steven M. Lichtman, MBA – Medical Gadgets
- Jay Olson, MBA, CFA – Biotechnology
- Hartaj Singh, MBA – Biotechnology
- Michael Wiederhorn, MA – Healthcare Suppliers
Erica L. Moffett, Managing Director and Affiliate Director of Analysis at Oppenheimer, mentioned, “The final 18 months have clearly bolstered the centrality of the life sciences and med tech industries throughout all points of our society and our financial system. We’re happy to have the ability to provide one other profitable digital convention, together with the chance for our shoppers to fulfill with administration groups to debate, intimately, key therapeutic packages in growth in addition to essential developments unfolding in these industries and up to date company updates.”
Oppenheimer & Co. Inc.
Oppenheimer & Co. Inc. (Oppenheimer), a principal subsidiary of Oppenheimer Holdings Inc. (OPY on the New York Inventory Change), and its associates present a full vary of wealth administration, securities brokerage and funding banking providers to high-net-worth people, households, company executives, native governments, companies and establishments. For extra data, please go to www.oppenheimer.com.
SOURCE Oppenheimer & Co. Inc.